ArQule, Inc. (ARQL)
ARQL Price and Sentiment
ARQL Latest news
Merck (NYSE: MRK) will acquire ArQule, Inc. (NASDAQ: ARQL) for $20 per share in cash for an approximate total equity value of $2.7 billion.
Merck said on Monday it would buy cancer drug developer ArQule in a $2.7 billion all-cash deal, bolstering its oncology franchise with the smaller rival's lead drug that is being tested as a treatment for blood cancer.
ArQule (ARQL) delivered earnings and revenue surprises of 0.00% and -82.67%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?
ArQule (ARQL) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
ArQule plunged 9% despite the absence of company-specific negative news.
On ArQule's (ARQL) second-quarter earnings call, investor focus will be on the company's early-stage pipeline candidates, which are under development for treating several cancers and rare diseases.
The pharmaceutical pipeline shined, and the business doubled its cash position.
Shares have risen by 50% since my last update piece.
The stock soared to its highest level in over 10 years on encouraging, early-stage clinical results.